For instance, Novo Nordisk was forced to cut its annual profit expectations back in August following weaker-than-expected ...

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly’s tirzepatide medicines face strong ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S. Last month, the FDA removed Eli Lilly ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

which both use a different GLP-1 agonist drug called semaglutide. Eli Lilly CEO Dave Ricks told investors during a call following the announcement that there wasn't a "demand problem here," but ...